Erratum: Guidelines for time-to-event end point definitions in breast cancer trials: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). [Ann Oncol, 26, (2015), 873-879] doi: 10.1093/annonc/mdv106;Guidelines for time-to-event end point definitions in breast cancer trials: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 873-879

  Gourgou Bourgade, Sophie ^a,b   Cameron, D ^c   Poortmans, P ^d   Asselain, B ^e   Azria, D ^a   Cardoso, F ^f   A'Hern, R ^g   Bliss, J ^g   Bogaerts, J ^h   Bonnefoi, H ⁱ   Brain, E ^e   Cardoso, M J ^f   Chibaudel, B ^j   Coleman, R ^k   Cufer, T ^l   Dal Lago, L ^m   Dalenc, F ⁿ   De Azambuja, E ^m   Debled, M ⁱ   Delaloge, S ^o   Filleron, T ⁿ   Gligorov, J ^p   Gutowski, M ^a   Jacot, W ^a   Kirkove, C ^q   MacGrogan, G ⁱ   Michiels, S ^o,r   Negreiros, I ^s   Offersen, B V ^t   Penault Llorca, F ^u,v   Pruneri, G ^w,x   Roche, H ⁿ   Russell, N S ^y   Schmitt, F ^z,aa   Servent, V ^ab   Thurlimann B ^ac   Untch, M ^ad   van der Hage, J A ^ae   van Tienhoven, G ^af   Wildiers, H ^ag,ah   Yarnold, J ^g   Bonnetain, F ^ai   Mathoulin Pelissier S ^i,aj   Bellera, C ^i,aj   Dabakuyo Yonli, T S ^ak   more..

^a CENTRE VAL D AURELLE   (France)

^b Data Center for Cancer Clinical Trials CTD INCa   (France)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d Institute Verbeeten   (Netherlands)

^e INSTITUT CURIE   (France)

^f Champalimaud Cancer Center   (Portugal)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h EORTC DATA CENTER   (Belgium)

ⁱ INSTITUT BERGONIÉ   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k WESTON PARK HOSPITAL   (United Kingdom)

^l UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^m JULES BORDET INSTITUTE   (Belgium)

ⁿ INSTITUT CLAUDIUS REGAUD   (France)

^o INSTITUT GUSTAVE ROUSSY   (France)

^p SORBONNE UNIVERSITÉ   (France)

^q UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^r UNIVERSITÉ PARIS SACLAY   (France)

^s CUF Descobertas Hospital   (Portugal)

^t AARHUS UNIVERSITY HOSPITAL   (Denmark)

^u CENTRE JEAN PERRIN   (France)

^v UNIVERSITÉ CLERMONT AUVERGNE   (France)

^w EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^x UNIVERSITY OF MILAN   (Italy)

^y NETHERLANDS CANCER INSTITUTE   (Netherlands)

^z UNIVERSITY OF PORTO   (Portugal)

^aa University of Porto   (Portugal)

^ab Oscar Lambret Comprehensive Cancer Center   (France)

^ac CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^ad HELIOS KLINIKUM BERLIN BUCH   (Germany)

^ae ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^af ACADEMIC MEDICAL CENTER   (Netherlands)

^ag UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ah UNIVERSITY OF LEUVEN   (Belgium)

^ai UNIVERSITY HOSPITAL OF BESANÇON   (France)

^aj Centre of Clinical Investigation Clinical Epidemiology   (France)

^ak CENTRE GEORGES FRANÇOIS LECLERC   (France)

more..

Author keywords

Breast cancer; Efficacy measure; Guidelines; Randomized, controlled trial; Time to event end point

Indexed keywords

BREAST CANCER; BREAST CANCER FREE INTERVAL; BREAST CANCER SPECIFIC SURVIVAL; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT DISEASE FREE SURVIVAL; DISTANT RECURRENCE FREE INTERVAL; DISTANT RELAPSE FREE SURVIVAL; GENERAL PATHOLOGICAL PARAMETERS; HEALTH CARE CONCEPTS; HUMAN; INVASIVE DISEASE FREE SURVIVAL; LOCAL RECURRENCE FREE SURVIVAL; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL TERMINOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; QUALITY CONTROL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE INTERVAL; RECURRENCE FREE SURVIVAL; REVIEW; STANDARDIZATION; STUDY DESIGN; TIME TO EVENT END POINT; TIME TO PROGRESSION; TREATMENT OUTCOME; VALIDATION PROCESS; BIOASSAY; BREAST NEOPLASMS; CLASSIFICATION; CONSENSUS; CONSENSUS DEVELOPMENT; DELPHI STUDY; DISEASE COURSE; FEMALE; METHODOLOGY; MORTALITY; NOMENCLATURE; STANDARDS; TIME FACTOR; TREATMENT FAILURE;

BREAST NEOPLASMS; CONSENSUS; DELPHI TECHNIQUE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT FAILURE;

EID: 84929091968     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv478     Document Type: Erratum

References (17)

1. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol Off J Am Soc Clin Oncol 2003; 21(7): 1404-1411.
2. International conference on harmonisation; guidance on statistical principles for clinical trials; availability-FDA. Notice. Fed Regist 1998; 63(179): 49583-49598.
3. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152(11): 726-732.
4. Mathoulin-Pélissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol Off J Am Soc Clin Oncol 2008; 26(22): 3721-3726.
5. Food and Drugs Administration DoHaHS. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville: US Department of Health and Human Services Food and Drug Administration 2007.
6. Punt CJA, Buyse M, Köhne C-H et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007; 99(13): 998-1003.
7. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100(10): 698-711.
8. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 2007; 25(5): 579-586.
9. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25(15): 2127-2132.
10. Bellera CA, Pulido M, Gourgou S et al. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised timeto-event endpoints' definitions in cancer clinical trials. Eur J Cancer Oxf Engl 1990 2013; 49(4): 769-781.
11. Fitch K. The Rand/UCLA Appropriateness Method User's Manual. Santa Monica: RAND 2001.
12. Haute Autorité de la Santé. élaboration de recommandations de bonne pratique Méthode "Recommandations pour la pratique clinique". 2010.
13. Thurlimann B et al. The Breast International Group (BIG) 1-98 collaborative group. N Engl J Med 2005; 353: 2747-2757.
14. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366(9484): 455-462.
15. Birgisson H, Wallin U, Holmberg L, Glimelius B. Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival. BMC Cancer 2011; 11: 438.
16. Nout RA, Fiets WE, Struikmans H et al. The in-or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat 2008; 109(3): 567-572.
17. COMET Initiative. http://www.comet-initiative.org (1 June 2014, date last accessed).